A Phase II Open Label Study of Toripalimab, a PD-1 Antibody, in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
Latest Information Update: 24 Feb 2023
At a glance
- Drugs Toripalimab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
Most Recent Events
- 21 Jan 2023 Results (n=15) presented at the 2023 Gastrointestinal Cancers Symposium
- 25 Apr 2022 Planned End Date changed from 30 Dec 2021 to 15 Jan 2024.
- 25 Apr 2022 Planned primary completion date changed from 30 Dec 2020 to 15 Jan 2024.